Interv Akut Kardiol 2010; 9(Suppl.B): 5-8

Percutaneous transluminal balloon valvuloplasty in patients with calcified aortic stenosis

Josef Šťásek¹, Josef Bis¹, Jan Vojáček¹, Miroslav Brtko², Pavel Polanský², Martin Vejběra³, Jaroslav Dušek¹, Dušan Černohorský⁴

Kardiocentrum FN Hradec Králové

¹ I. interní klinika, LF UK Hradec Králové

² Kardiochirurgická klinika, LF UK Hradec Králové

³ Klinika anesteziologie a resuscitace, LF UK Hradec Králové

⁴ Klinika geronto-metabolická, LF UK Hradec Králové

Aortic valve stenosis due to degenerative processes is currently the most common valvular defect in the adult population. Its prevalence

increases with age. The treatment of choice is surgical valve replacement. In 20–30 % of patients, mostly of advanced age, surgical

valve replacement cannot be performed. In 1985, professor Cibier carried out the first balloon dilatation of a stenotic aortic valve (BAV)

of this type. Soon afterwards, the effect of BAV was shown to be limited with early restenosis and a high risk associated with the procedure.

Despite a certain revival after the year 2000, BAV of a degenerated aortic valve remains a largely palliative approach which, as

a final procedure, is reserved for a very small group of predominantly very old patients. Another indication is an intervention performed

as a bridge to aortic valve replacement or to another surgical procedure in severely symptomatic patients with aortic valve stenosis. BAV

is the first step prior to a catheter-based aortic valve implantation. Despite a number of limitations, BAV is currently a feasible and safe

method with a decent short-term clinical effect.

Keywords: aortic valve defect, aortic valve stenosis, aortic valve balloon dilatation

Published: April 1, 2010  Show citation